Sutro Biopharma, Inc. STRO
Key Stats
- Today's Range
- $23.92 – $25.96
- 50-Day Range
- $21.72 – $34.05
- 52-Week Range
- $7.15 – $43.85
- Volume
- 169K shs
- Average Volume
- 383K shs
- Market Cap
- $420.56 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- -6.29
- Price / Sales
- 4.22
Short Interest
- Short Interest
- 0.07%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $99.61 million
- Net Income
- $-153,602,000
- Net Margin
- -154.21%
- Return on Equity
- 229.64%
- Debt-to-Equity
- —
About Sutro Biopharma, Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Related Stocks
Compare head-to-head: STRO vs AMGN·STRO vs HALO·STRO vs RGEN·STRO vs IMVT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.